The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account